Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations..docx
Supplementary Tables. Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations.
The implication of MET alterations in solid tumors and the immune microenvironment remains elusive.
Materials & Methods
FFPE samples of 21 patients with solid tumors harboring MET alterations were used for IHC staining. Extracted RNA was analyzed with the NanoString nCounter human PanCancer Immune Profiling Panel.
Patients were diagnosed with lung (N=10), breast (N=5), genitourinary (N=3), or colorectal cancer (N=3). Eleven had a MET missense mutation, 4 had an exon 14 splice site mutation, and 6 had MET amplification. CD6, CCL19, ATM, CD40LG, XCR1, MAGEA1, ATM and CCL19 genes were significantly differentially expressed in MET-altered cancers.